Home Cart Sign in  
Chemical Structure| 1609960-31-7 Chemical Structure| 1609960-31-7

Structure of TH588
CAS No.: 1609960-31-7

Chemical Structure| 1609960-31-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

TH588 is a highly selective inhibitor of MTH1 (NUDT1) with an IC50 of 5 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of TH588

CAS No. :1609960-31-7
Formula : C13H12Cl2N4
M.W : 295.17
SMILES Code : NC1=NC(C2=CC=CC(Cl)=C2Cl)=CC(NC3CC3)=N1
MDL No. :MFCD28963908
InChI Key :PNMYJIOQIAEYQL-UHFFFAOYSA-N
Pubchem ID :73389731

Safety of TH588

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of TH588

DNA

Isoform Comparison

Biological Activity

Target
  • MTH1

    MTH1, IC50:5 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
A431 cells 10 μM 24 hours Evaluate the anticancer activity of TH588 on A431 cells, with an IC50 value of 25 μM PMC7056313
HUVEC cells 200 μg/mL 24 hours To assess the biocompatibility of PP@T, results showed that even at higher concentrations, the viability of HUVEC cells remained above 85%. PMC11650535
4T1 cells 50 μg/mL 4 hours To evaluate the cellular uptake and antitumor effect of PP@T, results showed that PP@T significantly enhanced oxidative stress and apoptosis under ultrasound irradiation. PMC11650535
DoHH-2 0.5 µM 24 hours To study the effect of TH588 on DoHH-2 cell cycle, results showed TH588 induced G1 phase arrest and apoptosis. PMC7973795
Mino 0.5 µM 24 hours To evaluate the effect of TH588 on Mino cell cycle, results showed TH588 caused G2/M phase arrest and apoptosis. PMC7973795
BL-41 0.5 µM 24 hours To test the effect of TH588 on BL-41 cell viability, results showed TH588 significantly reduced viability and induced apoptosis. PMC7973795
U2OS cells 2 μM and 8 μM 48 hours Significantly inhibited U2OS cell growth PMC7063190
HOS-MNNG cells 2 μM and 8 μM 48 hours Significantly inhibited HOS-MNNG cell growth PMC7063190
4T1 200 μg/mL 24 hours Evaluate the toxicity of HTCG@TA on 4T1 cells, results showed only 6% cell survival PMC11653152
MCF-7 200 μg/mL 24 hours To evaluate the anti-tumor effects of NVP-CGM097 on p53 wild-type ER-positive breast cancer cells, showing cell cycle arrest and increased apoptosis. PMC11653152
MDA-MB-231 200 μg/mL 24 hours Evaluate the toxicity of HTCG@TA on MDA-MB-231 cells, results showed only 32% cell survival PMC11653152
A549 200 μg/mL 24 hours Evaluate cytotoxicity, showing low cytotoxicity PMC11653152
HUVEC 200 μg/mL 24 hours Evaluate the toxicity of HTCG@TA on normal cells, results showed over 80% cell survival PMC11653152

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice A431 tumor xenograft model Intravenous injection 50 μM Repeated every 5 days for 20 days Evaluate the therapeutic effect of TH588 and Ce6 combined therapy on A431 tumor xenograft model, showing significant tumor volume reduction PMC7056313
Balb/c mice 4T1 breast cancer model Intravenous injection 10 mg/kg Every 24 hours for 14 days To evaluate the antitumor effect of PP@T in vivo, results showed that PP@T combined with ultrasound irradiation significantly inhibited tumor growth and enhanced immune response. PMC11650535
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice BL-41-luc lymphoma xenograft model Oral gavage 90 mg/kg Twice a day, three times a week for 16 days To evaluate the anti-tumor effect of TH588 in vivo, results showed TH588 significantly inhibited tumor growth and prolonged survival. PMC7973795
BALB/c mice MCF-7 xenograft tumor model Intravenous injection 2.0 mg/mL (100 μL) Every other day for a total of four times Evaluate the anti-tumor effect of HTCG@TA in vivo, results showed significant tumor growth inhibition PMC11653152

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.39mL

0.68mL

0.34mL

16.94mL

3.39mL

1.69mL

33.88mL

6.78mL

3.39mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories